NASDAQ : ODTX

Odyssey Therapeutics, Inc.

$17.58 USD

-$0.03 (-0.17%)

Volume
223.14K
Average Volume
424.8K
Market Capitalization
$531.42M
P/E Ratio
-3.26
Dividend Yield
0.00%
Price Target
$35.00
Year High
$20.30
Year Low
$15.10
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$7.20
Company Overview

NASDAQ

Gary D. Glick

Biotechnology

Healthcare

ODTX

100

US

USD

https://odysseytx.com

(617) 865-9628

67613T104

0001882782

Liquidity Metrics

-0.06

7.20

7.20

1.57

0.00

Sales & Valuation

$2.98M

178.57

-0.99

-4.07

-4.74

Profitability

-$5.39

-$148.65M

-4994.86%

-5026.01%

30.44%

-55.10%

P/E Metrics

-3.26

-0.03

-0.03

Analyst Price Target & Rating

$35.00

$40.00

$30.00

Strong Sell

1/5

1 Analysts

-49.77%

Financial Health Scores

No financial score data available.

Key Metrics (TTM)

$516.84M

173.67

-3.57

7.20

30.44%

-64.44%

-30.68%

-24.59%

0 days

Company Executives
Name Title
Gary D. Glick Founder, President, CEO & Director
Eicke Latz Scientific Co-Founder
Collin Todd Senior Vice President of Strategy & Business Development
Jason Haas Chief Financial Officer
Joseph McDonald Chief Data Officer
Natalie Dales Chief of Research Operations & Portfolio Strategy
Jolie Siegel Executive VP, General Counsel & Secretary
Felix Meissner Scientific Co-Founder
Florian.I Schmidt Scientific Co-Founder
Kim Lewis Scientific Co-Founder
Poll Results

No votes yet today — be the first to share your view!

About Odyssey Therapeutics, Inc. (NASDAQ:ODTX) Stock

Odyssey Therapeutics, Inc. is a clinical-stage biopharmaceutical firm focused on discovering and developing novel treatments for autoimmune and inflammatory diseases. Its diverse pipeline features several key drug candidates: OD-001, an oral small molecule that inhibits receptor-interacting protein kinase 2, which is currently in Phase 2a clinical trials for ulcerative colitis. Also included is OD-002, an oral small molecule SLC15A4 inhibitor engineered to prevent harmful inflammatory responses driven by TLR7/8/9-mediated activation of interferon regulatory factor 5 (IRF5). Another program, OD-003, is a protein therapeutic designed to selectively agonize tumor necrosis factor receptor 2 on T regulatory cells. Further assets in its portfolio comprise a bispecific antagonist targeting TSLP a ... nd IL-33, an oral small molecule functioning as an interleukin-1 receptor-associated kinase 4 scaffolding inhibitor, and a separate small molecule inhibitor specifically targeting IRF5. The company was founded in 2021 and is headquartered in Boston, Massachusetts.

Odyssey Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

2026-06-17 16:15:00

Reported positive clinical proof-of-concept data for OD-001, our first-in-class, oral RIPK2 scaffolding inhibitor, in a Phase 2a monotherapy trial for moderate to severe ulcerative colitis Cash on hand as of March 31, 2026, together with net proceeds from the IPO, and concurrent private placement, of $464M expected to fund operations into the second half of 2028 BOSTON, June 17, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (Nasdaq: ODTX) (“Odyssey” or the “Company”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that precisely target disease pathology, today reported financial results for the first quarter ended March 31, 2026 and highlighted progress across its clinical and preclinical portfolio. “During the quarter, we continued to build meaningful momentum and made significant progress across our portfolio, including delivering clinical proof-of-concept for our oral, small molecule, RIPK2 scaffolding inhibitor, OD-001, in moderate-to-severe ulcerative colitis,” said Gary D.

Healthcare IPOs Raise $4.7 Billion As Odyssey, Mobia Debuts Slip

2026-05-11 07:31:00

Healthcare IPO demand is coming back, but investors are not giving every new listing an easy first-day win. Odyssey Therapeutics (ODTX) and Mobia Medical (MOBI)

Odyssey Therapeutics Announces Pricing of Upsized Initial Public Offering

2026-05-07 20:44:00

BOSTON, May 07, 2026 (GLOBE NEWSWIRE) -- Odyssey Therapeutics, Inc. (“Odyssey”), a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases by developing medicines that are designed to precisely target disease pathology, today announced the pricing of its upsized initial public offering of 15,500,000 shares of its common stock at an initial public offering price of $18.00 per share. In addition, Odyssey has granted the underwriters a 30-day option to purchase up to an additional 2,325,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions.

Frequently Asked Questions

What is the current Odyssey Therapeutics, Inc. (ODTX) stock price?

Odyssey Therapeutics, Inc.(NASDAQ:ODTX) stock price is $17.58 in the last trading session. During the trading session, ODTX stock reached the peak price of $20.3 while $15.1 was the lowest point it dropped to. The percentage change in ODTX stock occurred in the recent session was --0.17% while the dollar amount for the price change in ODTX stock was -$0.03.

ODTX's industry and sector of operation?

The NASDAQ listed ODTX is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of ODTX?

Gary D. Glick | Founder, President, CEO & Director
Eicke Latz | Scientific Co-Founder
Collin Todd | Senior Vice President of Strategy & Business Development
Jason Haas | Chief Financial Officer
Joseph McDonald | Chief Data Officer

How many employees does ODTX have?

Number of ODTX employees currently stands at 100. ODTX operates from 51 Sleeper Street, Boston, MA 02210, US.

Link for ODTX official website?

Official Website of ODTX is: https://odysseytx.com

How do I contact ODTX?

ODTX could be contacted at phone #(617) 865-9628 and can also be accessed through its website. ODTX operates from 51 Sleeper Street, Boston, MA 02210, US.

How many shares of ODTX are traded daily?

The average number of ODTX shares traded daily for last 3 months was 424.8K.

What is the market cap of ODTX currently?

The market value of ODTX currently stands at $531.42M with its latest stock price at $17.58